Evaluation of a new antianginal agent, nipradilol, in effort angina using holter monitoring.

Publisher Website
Google Scholar
Abstract
The purpose of this study was to investigate the efficacy, effective dose, administration frequency and antianginal effect of a new antianginal agent, nipradilol, in 12 patients with stable effort angina. A single blind design was employed; the test consisted of an observation period (1 week) and a treatment period (1-2 weeks). Twenty four hour Holter monitoring was performed on the penultimate day of each period. Nipradilol was administered twice a day at a daily dose of 3-12 mg (mean 7.9 .+-. 3.3 mg). The mean frequency of ST-segment depression was 7.1 .+-. 6.7 times per day at baseline and 3.1 .+-. 2.7 after drug administration, showing a significant reduction (p < 0.05). The suppression of ST-segment depression and decrease in heart rate due to this drug persisted for 12 hours following administration. The plasma drug concentration at a daily dose of 12 mg peaked at 9.5 .+-. 2.4 ng/ml 1 hour after administration and the 12 hour value was 2.3 .+-. 1.2 ng/ml. No side effects were observed. Therefore, it seems that, when administered twice a day (total daily dose 6 mg) this drug is effective in effort angina and that the antianginal effect is mainly attributable to .beta.-adrenoceptor blockade.

This publication has 0 references indexed in Scilit: